Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer

BACKGROUND: Resistance to endocrine therapy in estrogen receptor–positive (ER+) breast cancer remains a significant clinical problem. Riluzole is FDA-approved for the treatment of amyotrophic lateral sclerosis. A benzothiazole-based glutamate release inhibitor with several context-dependent mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales: Olukoya, Ayodeji O, Stires, Hillary, Bahnassy, Shaymaa, Persaud, Sonali, Guerra, Yanira, Ranjit, Suman, Ma, Shihong, Cruz, M Idalia, Benitez, Carlos, Rozeboom, Aaron M, Ceuleers, Hannah, Berry, Deborah L, Jacobsen, Britta M, Raj, Ganesh V, Riggins, Rebecca B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521904/
https://www.ncbi.nlm.nih.gov/pubmed/37766843
http://dx.doi.org/10.1210/jendso/bvad117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521904/
https://www.ncbi.nlm.nih.gov/pubmed/37766843
http://dx.doi.org/10.1210/jendso/bvad117

Ejemplares similares